Dalia Ercan

8.9k total citations · 2 hit papers
20 papers, 3.7k citations indexed

About

Dalia Ercan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Dalia Ercan has authored 20 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Dalia Ercan's work include Lung Cancer Treatments and Mutations (16 papers), Cancer therapeutics and mechanisms (8 papers) and HER2/EGFR in Cancer Research (5 papers). Dalia Ercan is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer therapeutics and mechanisms (8 papers) and HER2/EGFR in Cancer Research (5 papers). Dalia Ercan collaborates with scholars based in United States, South Korea and China. Dalia Ercan's co-authors include Pasi A. Jänne, Nathanael S. Gray, Marzia Capelletti, Michael J. Eck, Kwok‐Kin Wong, Cai‐Hong Yun, Geoffrey R. Oxnard, J. Carl Barrett, Aleksandra Markovets and Enriqueta Felip and has published in prestigious journals such as Nature, Cell and Nature Medicine.

In The Last Decade

Dalia Ercan

19 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. Nature Medicine profile →
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

2009 785 citations Wenjun Zhou, Dalia Ercan et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dalia Ercan United States	15	2.4k	2.2k	2.0k	766	437	20	3.7k
Victoria Zazulina United Kingdom	14	3.9k 1.7×	1.7k 0.8×	3.4k 1.7×	882 1.2×	245 0.6×	23	4.7k
Courtney Hyland United States	2	2.1k 0.9×	1.9k 0.9×	2.0k 1.0×	683 0.9×	152 0.3×	4	3.6k
Shunpei Ishikawa Japan	20	3.0k 1.3×	2.2k 1.0×	2.5k 1.2×	1.3k 1.7×	805 1.8×	27	5.3k
Danan Li United States	16	1.0k 0.4×	2.3k 1.1×	1.6k 0.8×	496 0.6×	236 0.5×	21	3.2k
Andrew M. Rogers United States	12	2.7k 1.1×	2.4k 1.1×	2.6k 1.3×	994 1.3×	179 0.4×	21	4.7k
Eugene Lifshits United States	12	1.6k 0.7×	1.6k 0.7×	1.6k 0.8×	367 0.5×	194 0.4×	13	2.6k
Kreshnik Zejnullahu United States	9	3.2k 1.3×	3.1k 1.4×	3.1k 1.5×	956 1.2×	300 0.7×	17	5.5k
Kenneth S. Thress United States	26	4.0k 1.7×	2.5k 1.1×	3.4k 1.7×	1.9k 2.5×	289 0.7×	48	5.7k
Riyaz Shah United Kingdom	19	3.3k 1.4×	1.1k 0.5×	2.8k 1.3×	708 0.9×	163 0.4×	48	3.9k
Kristen E. Mengwasser United States	7	1.1k 0.5×	1.5k 0.7×	1.1k 0.6×	523 0.7×	236 0.5×	8	2.4k

Countries citing papers authored by Dalia Ercan

Since Specialization

Citations

This map shows the geographic impact of Dalia Ercan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dalia Ercan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dalia Ercan more than expected).

Fields of papers citing papers by Dalia Ercan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dalia Ercan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dalia Ercan. The network helps show where Dalia Ercan may publish in the future.

Co-authorship network of co-authors of Dalia Ercan

This figure shows the co-authorship network connecting the top 25 collaborators of Dalia Ercan. A scholar is included among the top collaborators of Dalia Ercan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dalia Ercan. Dalia Ercan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Colin, Christelle, Dalia Ercan, Eric A. Welsh, et al.. (2025). A machine learning framework for classifying lipids in untargeted metabolomics using mass-to-charge ratios and retention times. Metabolomics. 21(6). 151–151.

Grass, G. Daniel, Dalia Ercan, Timothy I. Shaw, et al.. (2023). An Assessment of the Penile Squamous Cell Carcinoma Surfaceome for Biomarker and Therapeutic Target Discovery. Cancers. 15(14). 3636–3636. 1 indexed citations

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

Chong, Curtis R., Magda Bahcall, Marzia Capelletti, et al.. (2016). Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research. 23(1). 204–213. 67 indexed citations

Xu, Chunxiao, Sharmeen Uddin, Marzia Capelletti, et al.. (2015). Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer. Cancer Discovery. 5(9). 960–971. 159 indexed citations

Ercan, Dalia, Hwan Geun Choi, Cai‐Hong Yun, et al.. (2015). EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research. 21(17). 3913–3923. 291 indexed citations

Tanizaki, Junko, Dalia Ercan, Marzia Capelletti, et al.. (2015). Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research. 75(15). 3139–3146. 30 indexed citations

Montero, Joan, Kristopher A. Sarosiek, Joseph D. DeAngelo, et al.. (2015). Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy. Cell. 160(5). 977–989. 252 indexed citations

Thress, Kenneth S., Cloud P. Paweletz, Enriqueta Felip, et al.. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine. 21(6). 560–562. 1189 indexed citations breakdown →

10.

Capelletti, Marzia, Michael Dodge, Dalia Ercan, et al.. (2014). Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma. Clinical Cancer Research. 20(24). 6551–6558. 79 indexed citations

11.

Calles, Antonio, et al.. (2014). Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines. Molecular Oncology. 9(1). 260–269. 52 indexed citations

12.

Xie, Ting, Sang Min Lim, Kenneth D. Westover, et al.. (2014). Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology. 10(12). 1006–1012. 162 indexed citations

13.

Xu, Lu, Eiki Kikuchi, Chunxiao Xu, et al.. (2012). Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET. Cancer Research. 72(13). 3302–3311. 88 indexed citations

14.

Cortot, Alexis B., Claire E. Repellin, Takeshi Shimamura, et al.. (2012). Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research. 73(2). 834–843. 163 indexed citations

15.

Capelletti, Marzia, Doron Lipson, Geoff Otto, et al.. (2012). Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.. Journal of Clinical Oncology. 30(15_suppl). 7510–7510. 4 indexed citations

16.

Ercan, Dalia, Ting Xie, Marzia Capelletti, Nathanael S. Gray, & Pasi A. Jänne. (2012). Abstract 4832: Novel EGFR mutations that cause drug resistance to irreversible pyrimidine but not quinazoline based EGFR inhibitors. Cancer Research. 72(8_Supplement). 4832–4832. 5 indexed citations

17.

Ercan, Dalia, Wenjun Zhou, Masahiko Yanagita, et al.. (2011). Abstract 4736: Amplification of ERK2 mediates resistance to the novel irreversible EGFR inhibitor WZ4002. Cancer Research. 71(8_Supplement). 4736–4736. 1 indexed citations

18.

Ercan, Dalia, Kreshnik Zejnullahu, Kimio Yonesaka, et al.. (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 29(16). 2346–2356. 181 indexed citations

19.

Zhou, Wenjun, Dalia Ercan, Pasi A. Jänne, & Nathanael S. Gray. (2010). Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorganic & Medicinal Chemistry Letters. 21(2). 638–643. 48 indexed citations

20.

Zhou, Wenjun, Dalia Ercan, Liang Chen, et al.. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 462(7276). 1070–1074. 785 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact